Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:289
Structure:
Synonyms:
1,2-benzenediol
1,2-dihydroxybenzene
1,3-dihydroxybenzene
120-80-9
12385-08-9
135011_SIAL
16474-89-8
16474-90-1
2-(5,8-Dihydroxy-1-methoxy-3-methyl(2-naphthyl))-5-methoxy-7-methylnaphthalene-1,4-diol
2-hydroxyphenol
20244-21-7
20244-21-7 (unspecified hydrochloride salt)
37349-32-9
4-06-00-05557 (Beilstein Handbook Reference)
430749_ALDRICH
430749_SIAL
AB-131/40235236
AB1002105
AC1L18WM
AC1Q78GA
AG-D-45381
AI3-03995
AIDS-108194
AIDS108194
AKOS000119002
alpha-hydroxyphenol
BBL002408
BB_NC-2239
Benzcatechin
Benzene, o-dihydroxy-
benzene-1,2-diol
benzenediol
BIDD:ER0327
bmse000385
Brenzcatechin
BRN 0471401
C 9510
C.I. 76500
C.I. Oxidation Base 26
C00090
c0097
C01785
C034221
C15571
C3561_SIAL
C9510_SIAL
C9593_SIGMA
CAQ
Catechin
Catechin (phenol)
CATECHOL
Catechol (phenol)
catechol dipotassium salt
catechol sodium salt
catechol, 14C-labeled cpd
Catechol-pyrocatechol
Catechol-UL-14C
CCG-204375
CCRIS 741
CHEBI:18135
CHEMBL280998
CI 76500
CI Oxidation Base 26
DB02232
Dihydroxybenzene
Durafur developer C
Durafur Developer CFouramine PCH
EINECS 204-427-5
EU-0100280
Fouramine PCH
Fourrine 68
HMS2233A17
HMS3260H22
HSDB 1436
I01-2906
Katechol
Katechol [Czech]
Lopac-C-9510
Lopac0_000280
LS-637
MLS002153385
MLS002303022
MolPort-000-871-939
NCGC00015283-01
NCGC00015283-02
NCGC00015283-03
NCGC00015283-04
NCGC00015283-05
NCGC00015283-06
NCGC00015283-07
NCGC00015283-08
NCGC00091262-01
NCGC00091262-02
NCGC00091262-03
nchembio801-comp10
NCI-C55856
NSC 1573
NSC1573
o Dihydroxybenzene
o-Benzenediol
o-Dihydroxybenzene
o-Dioxybenzene
o-Diphenol
o-Hydroquinone
o-Hydroxyphenol
o-Phenylenediol
ortho-Benzenediol
ortho-Dihydroxybenzene
ortho-Dioxybenzene
ortho-Hydroquinone
ortho-Hydroxyphenol
ortho-Phenylenediol
Oxyphenic acid
P0317
P0567
Pelagol Grey C
phenol derivative, 2
Phthalhydroquinone
pyrocatechin
Pyrocatechine
Pyrocatechinic acid
Pyrocatechinic acidPyrocatechol
pyrocatechol
pyrocatechol-ul-14C
Pyrocatechuic acid
Pyrokatechin
Pyrokatechin [Czech]
Pyrokatechol
Pyrokatechol [Czech]
SMR000326660
ST5214346
STK398651
WLN: QR BQ
ZINC13512214

Target

show target details
Uniprot ID:EDNRA_MOUSE
Synonyms:
Endothelin A receptor
Endothelin-1 receptor
ET-A
ET-AR
EC-Numbers:-
Organism:Mouse
Mus musculus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

16818507
Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.. Francesca Spinella; Laura Rosan˛; Valeriana Di Castro; Samantha Decandia; Adriana Albini; Maria Rita Nicotra; Pier Giorgio Natali; Anna Bagnato (2006) Molecular cancer therapeutics display abstract
The polyphenol epigallocatechin-3-gallate (EGCG), the principal mediator of the green tea, has been known to possess antitumor effect. The endothelin A receptor (ET(A)R)/endothelin-1 (ET-1) axis is overexpressed in ovarian carcinoma representing a novel therapeutic target. In this study, we examined the green tea and EGCG effects on two ovarian carcinoma cell lines, HEY and OVCA 433. EGCG inhibited ovarian cancer cell growth and induced apoptosis that was associated with a decrease in Bcl-X(L) expression and activation of caspase-3. Treatment with green tea or EGCG inhibited ET(A)R and ET-1 expression and reduced the basal and ET-1-induced cell proliferation and invasion. The EGCG-induced inhibitory effects were associated with a decrease of ET(A)R-dependent activation of the p42/p44 and p38 mitogen-activated protein kinases and phosphatidylinositol 3-kinase pathway. Remarkably, EGCG treatment resulted in a lowering of basal and ET-1-induced angiogenesis and invasiveness mediators, such as vascular endothelial growth factor and tumor proteinase activation. Finally, in HEY ovarian carcinoma xenografts, tumor growth was significantly inhibited by oral administration of green tea. This effect was associated with a reduction in ET-1, ET(A)R, and vascular endothelial growth factor expression, microvessel density, and proliferation index. These results provide a novel insight into the mechanism by which EGCG, affecting multiple ET(A)R-dependent pathways, may inhibit ovarian carcinoma growth, suggesting that EGCG may be useful in preventing and treating ovarian carcinoma in which ET(A)R activation by ET-1 plays a critical role in tumor growth and progression.